Effect of intraoperative HES 6% 130/0.4 on the need for blood transfusion after major oncologic surgery: a propensity-matched analysis

Imagem de Miniatura
Arquivos
art_RANZANI_Effect_of_intraoperative_HES_6%_130_0_4_2013.PDF (415.91 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2013
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
ZAMPIERI, Fernando Godinho
MORATO, Priscila Fernanda
CAMPOS, Pedro Paulo
Citação
CLINICS, v.68, n.4, p.501-509, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: To evaluate the effect of the intraoperative use of hydroxyethyl starch on the need for blood products in the perioperative period of oncologic surgery. The secondary end-points included the need for other blood products, the clotting profile, the intensive care unit mortality and length of stay. METHODS: Retrospective observational analysis in a tertiary oncologic ICU in Brazil including 894 patients submitted to oncologic surgery for a two-year period from September 2007. Patients were grouped according to whether hydroxyethyl starch was used during surgery (hydroxyethyl starch and No-hydroxyethyl starch groups) and compared using a propensity score analysis. A total of 385 propensity-matched patients remained in the analysis (97 in the No-hydroxyethyl starch group and 288 in the hydroxyethyl starch group). RESULTS: A higher percentage of patients in the hydroxyethyl starch group required red blood cell transfusion during surgery (26% vs. 14%; p = 0.016) and in the first 24 hours after surgery (5% vs. 0%; p = 0.015) but not in the 24-to 48-hour period after the procedure. There was no difference regarding the transfusion of other blood products, intensive care unit mortality or length of stay. CONCLUSION: Hydroxyethyl starch use in the intraoperative period of major oncologic surgery is associated with an increase in red blood cell transfusions. There are no differences in the need for other blood products, intensive care unit length of stay or mortality.
Palavras-chave
Tetrastarch, Adverse Events, Blood Transfusion, Surgical Blood Loss, Surgery, Cancer
URI
https://observatorio.fm.usp.br/handle/OPI/2302
Referências
  1. Abosaif NY, 2005, AM J KIDNEY DIS, V46, P1038, DOI 10.1053/j.ajkd.2005.08.033
  2. Amar D, 2003, ANESTHESIOLOGY, V98, P337, DOI 10.1097/00000542-200302000-00011
  3. Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
  4. Bellmann R, 2012, CLIN PHARMACOKINET, V51, P225, DOI 10.2165/11594700-000000000-00000
  5. Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149
  6. Brookhart MA, 2006, EPIDEMIOLOGY, V17, P373, DOI 10.1097/01.ede.0000222026.42077.ee
  7. Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716
  8. Corcoran T, 2012, ANESTH ANALG, V114, P640, DOI 10.1213/ANE.0b013e318240d6eb
  9. D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
  10. de Jonge E, 2001, CRIT CARE MED, V29, P1261, DOI 10.1097/00003246-200106000-00038
  11. Doherty M, 2012, BRIT J ANAESTH, V109, P69, DOI 10.1093/bja/aes171
  12. Drews RE, 2003, CLIN CHEST MED, V24, P607, DOI 10.1016/S0272-5231(03)00100-X
  13. Dubniks M, 2007, INTENS CARE MED, V33, P293, DOI 10.1007/s00134-006-0454-5
  14. Franz A, 2001, ANESTH ANALG, V92, P1402
  15. Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6
  16. Gayat E, 2010, INTENS CARE MED, V36, P1993, DOI 10.1007/s00134-010-1991-5
  17. Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358
  18. Hahn RG, 2010, ANESTHESIOLOGY, V113, P470, DOI 10.1097/ALN.0b013e3181dcd88f
  19. Hartog CS, 2011, INTENS CARE MED, V37, P1725, DOI 10.1007/s00134-011-2385-z
  20. Hartog CS, 2011, ANESTH ANALG, V112, P635, DOI 10.1213/ANE.0b013e31820ad607
  21. Hayden SJ, 2012, AM J RESP CRIT CARE, V185, P1049, DOI 10.1164/rccm.201110-1915CI
  22. James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229
  23. Komatsu Y, 2012, WORLD J SURG, V36, P844, DOI 10.1007/s00268-012-1433-3
  24. Kozek-Langenecker SA, 2005, ANESTHESIOLOGY, V103, P654, DOI 10.1097/00000542-200509000-00031
  25. Kozek-Langenecker SA, 2008, ANESTH ANALG, V107, P382, DOI 10.1213/ane.0b013e31817e6eac
  26. Kvolik S, 2010, SURG ONCOL, V19, pE33, DOI 10.1016/j.suronc.2009.03.008
  27. Langeron O, 2001, ANESTH ANALG, V92, P855
  28. Lobo SM, 2011, CRIT CARE, V15, DOI 10.1186/cc10466
  29. Miletin MS, 2002, INTENS CARE MED, V28, P917, DOI 10.1007/s00134-002-1337-z
  30. Ng T, 2012, J THORAC CARDIOV SUR, V143, P815, DOI 10.1016/j.jtcvs.2011.12.031
  31. Perel P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub4
  32. Perisanidis C, 2012, ORAL ONCOL, V48, P372, DOI 10.1016/j.oraloncology.2011.11.020
  33. Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242
  34. Persson J, 2006, CRIT CARE MED, V34, P2456, DOI 10.1097/01.CCM.0000233876.87978.AB
  35. Prowle JR, 2011, CRIT CARE, V15, DOI 10.1186/cc10318
  36. Rzyman W, 2003, J THORAC CARDIOV SUR, V126, P755, DOI 10.1016/S0022-5223(03)00217-4
  37. Schortgen F, 2004, INTENS CARE MED, V30, P2222, DOI 10.1007/s00134-004-2415-1
  38. Schramko A, 2010, BRIT J ANAESTH, V104, P691, DOI 10.1093/bja/aeq084
  39. Singer M, 2012, CURR OPIN ANESTHESIO, V25, P96, DOI 10.1097/ACO.0b013e32834e8150
  40. Sossdorf M, 2009, CRIT CARE, V13, DOI 10.1186/cc8223
  41. Trof RJ, 2010, INTENS CARE MED, V36, P697, DOI 10.1007/s00134-010-1776-x
  42. Verheij J, 2006, INTENS CARE MED, V32, P1030, DOI 10.1007/s00134-006-0195-5
  43. Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - ODS/03